Pfizer or Moderna: Which mRNA COVID-19 vaccine works better over time?

• Facebook
• Twitter
• Reddit
• Tumblr
• LinkedIn
• Pinterest
• RSS Feed
• Link

Pfizer or Moderna: Which mRNA COVID-19 vaccine works better over time?

• Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
• Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
• FDA has mandated a top-level black box warning for all marketed CAR-T therapies
• Can people with high blood pressure eat peanuts?
• What is the difference between dopamine and dobutamine?
• How long can the patient live after heart stent surgery?

Pfizer or Moderna: Which mRNA COVID-19 vaccine works better over time?  In the real world, which mRNA vaccine works better over time?

Emerging Covid-19 variants and post-vaccination breakthrough infections underscore the need to study the effectiveness of current Covid-19 vaccines in the real world.

Up to now, only two mRNA COVID-19 vaccines have been approved for marketing, namely mRNA-1273 developed by Moderna and BNT162b2 developed by Pfizer /BioNTech .

Facts have proved that these two mRNAs are very effective in preventing severe illness, hospitalization and death caused by COVID-19 infection. efficient.

However, the humoral immune responses induced by the two mRNA vaccines were different, and data showed that the humoral antibody response to two doses of mRNA-1273 vaccine was significantly higher than that of two doses of BNT162b2 vaccine. And a higher humoral antibody response means a stronger protection against the COVID-19.

In addition, there are data showing that, during the Delta epidemic period, the breakthrough infection after two doses of BNT162b2 vaccine was higher than that after two doses of mRNA-1273 vaccine. These all suggest to us that these two mRNA vaccines may have different effects in the real world .

On May 2, 2022, researchers from the scientific healthcare organization Optum Labs published a research paper titled: Comparative effectiveness over time of the mRNA-1273 (Moderna) vaccine and the BNT162b2 (Pfizer-BioNTech) vaccine in the journal Nature Communications .

This retrospective cohort study investigated the relationship between COVID-19 infection and severity and timing of vaccination among nearly 4 million individuals in the United States who received two doses of the mRNA-1273 or BNT162b2 vaccine to understand how the two mRNA vaccines actually performed and Effectiveness comparison.

The primary outcome of the study was the rate of COVID-19 infection at 30, 60, and 90 days after the second dose of mRNA-1273 vaccine or BNT162b2 vaccine.

Of the nearly 4 million individuals who received two doses of the mRNA-1273 vaccine (40%) or the BNT162b2 vaccine (60%) , a total of 8,848 were documented to be infected with COVID-19, of which 3,090 (35%) had previously received mRNA -1273 vaccine, 5758 (65%) had been previously vaccinated against BNT162b2.

The statistical results showed that there was a statistically significant difference in infection over time between vaccination with mRNA-1273 and vaccination with BNT162b, and the probability of infection with the COVID-19 over time after vaccination with mRNA-1273 was lower.

But there was no statistically significant difference over time between the two mRNA vaccines for hospitalization, ICU admission, death, or transfer to hospice.

This large-scale retrospective analysis showed a significant difference in protection against SARS-CoV-2 infection between mRNA-1273 and BNT162b vaccination, and this difference widened over time.

The data showed that for every 1 million people who received two doses of the mRNA vaccine, at day 90, the number of people who received the BNT162b vaccine had 3,448 more breakthrough infections than those who received the mRNA-1273 vaccine.

Overall, after complete vaccination with either mRNA-1273 vaccine or BNT162b vaccine, mRNA-1273 vaccine was slightly more effective against infection than BNT162b vaccine.

But the two vaccines were equally effective in preventing severe illness (hospitalization, ICU, or death) within 90 days of full vaccination .

Reference :
https://www.nature.com/articles/s41467-022-30059-3

Pfizer or Moderna: Which mRNA COVID-19 vaccine works better over time?

(source:internet, reference only)

Disclaimer of medicaltrend.org

Important Note: The information provided is for informational purposes only and should not be considered as medical advice.